YD Bio Limited ('YD Bio Ltd” or the 'Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer ...

Patent covers pristine graphene–based biosensor technology to translate protease activity into measurable optical ...

Bio-Techne develops specialized reagents and diagnostic solutions for global research and clinical markets in the life ...

The European Patent Office (EPO) upholds bit.bio's patent for its dual genomic safe harbour technology, opti-ox™, securing the broadest possible claims for programming of pluripotent stem cells (PSCs) ...

Labware for 3D cell culture, low-bind labware, and glycan analysis kits are designed to accelerate life science ...

The global biopharmaceutical community is preparing to gather in Lisbon, Portugal, for the 20th edition of BIO-Europe Spring®, the premier springtime partnering conference for the industry, taking ...

The intellectual property will enhance Liberate Bio’s LNP platform for selective programming of monocytes and macrophages.

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and rema ...

INmune Bio's ATM offering before Phase II results shocked investors, raising $19M but signaling potential lack of confidence in positive trial outcomes. Phase II results for XPro failed to meet the ...

SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte ...